Status:

TERMINATED

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

Lead Sponsor:

Guerbet

Conditions:

Renal Artery Stenosis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.

Detailed Description

Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.

Eligibility Criteria

Inclusion

  • Male or female, aged more than 18 years,
  • Strongly suspected of having renal arterial disease,
  • Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination,

Exclusion

  • Known grade IV or V chronic kidney disease (GFR\<30 mL/min/1.73m²),
  • Contraindication to MRI,
  • Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination,

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2010

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT00845702

Start Date

April 1 2009

End Date

February 1 2010

Last Update

May 20 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Guerbet LLC

Bloomington, Indiana, United States, 47403